Terms: = Ovarian cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Diagnosis
889 results:
1. Prevalence and spectrum of germline brca1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.
De Matteis E; Tumolo MR; Tarantino P; Ciccarese M; Grassi T; Bagordo F; De Giorgio MR; Rizzo E; Ronzino G
Oncotarget; 2024 Feb; 15():134-141. PubMed ID: 38386807
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of Homologous Recombination Deficiency in ovarian cancer.
Ratnaparkhi R; Javellana M; Jewell A; Spoozak L
Curr Treat Options Oncol; 2024 Feb; 25(2):237-260. PubMed ID: 38300479
[TBL] [Abstract] [Full Text] [Related]
3. Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors.
Peleg Hasson S; Shachar E; Brezis MR; Saad A; Toledano B; Michaan N; Laskov I; Grisaru D; Goldstein J; Nutman A; Safra T
Int J Gynecol Cancer; 2024 Apr; 34(4):559-565. PubMed ID: 38242547
[TBL] [Abstract] [Full Text] [Related]
4. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to brca1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
5. Beyond BRCA: diagnosis and management of homologous recombination repair deficient pancreatic cancer.
LaRose M; Manji GA; Bates SE
Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
[TBL] [Abstract] [Full Text] [Related]
6. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
[TBL] [Abstract] [Full Text] [Related]
7. A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome.
Kotaka S; Yasui H; Tsubouchi H; Mori M; Kotani H; Yoshimura A; Ouchi A; Okuno M; Komori K; Shimizu Y; Suzuki S
Nagoya J Med Sci; 2023 Nov; 85(4):814-821. PubMed ID: 38155625
[TBL] [Abstract] [Full Text] [Related]
8. Cerebellar metastasis of ovarian cancer: a case report.
Cabitza E; Pirola M; Baldessari C; Bernardelli G; Zunarelli E; Pipitone S; Vitale MG; Nasso C; Molinaro E; Oltrecolli M; D'Agostino E; Mandato VD; Palicelli A; Dominici M; Sabbatini R
J Med Case Rep; 2023 Dec; 17(1):553. PubMed ID: 38115068
[TBL] [Abstract] [Full Text] [Related]
9. Pregnancy After Breast cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M; Blondeaux E; Agostinetto E; Hamy AS; Kim HJ; Di Meglio A; Bernstein Molho R; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips KA; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Del Mastro L; Puglisi F; Del Pilar Estevez-Diz M; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sánchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berlière M; Salama M; De Giorgi U; Sonnenblick A; Chiodi C; Lee YJ; Maria C; Azim HA; Boni L; Partridge AH;
JAMA; 2024 Jan; 331(1):49-59. PubMed ID: 38059899
[TBL] [Abstract] [Full Text] [Related]
10. Aneuploidy Landscape in Precursors of ovarian cancer.
Wang Y; Douville C; Chien YW; Wang BG; Chen CL; Pinto A; Smith SA; Drapkin R; Chui MH; Numan T; Vang R; Papadopoulos N; Wang TL; Shih IM
Clin Cancer Res; 2024 Feb; 30(3):600-615. PubMed ID: 38048050
[TBL] [Abstract] [Full Text] [Related]
11. Pathogenic germline variants in non-brca1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
12. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
13. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
14. Specialty Care and Counselling about Hereditary cancer Risk Improves Adherence to cancer Screening and Prevention in Newfoundland and Labrador Patients with
Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
[TBL] [Abstract] [Full Text] [Related]
15. The Tumor Suppressor brca1/2, cancer Susceptibility and Genome Instability in Gynecological and Mammary cancers.
Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
[TBL] [Abstract] [Full Text] [Related]
16. Is There a Role for Risk-Reducing Bilateral Breast Surgery in
Oliveira D; Fernandes S; Miguel I; Fragoso S; Vaz F
Curr Oncol; 2023 Aug; 30(9):7810-7817. PubMed ID: 37754482
[TBL] [Abstract] [Full Text] [Related]
17. Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.
Del Giglio A; da Costa Aguiar Alves B; Murad AM; Fonseca FLA
J Med Case Rep; 2023 Sep; 17(1):407. PubMed ID: 37743480
[TBL] [Abstract] [Full Text] [Related]
18. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract] [Full Text] [Related]
19. Short-term Impact of Hormone Replacement Therapy on Risk of Breast cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
[TBL] [Abstract] [Full Text] [Related]
20. [ovarian cancer: molecular pathology and molecularly targeted therapy].
Reis H; Völkl L; Demes M; Moinfar F; Wild PJ
Pathologie (Heidelb); 2023 Sep; 44(5):320-328. PubMed ID: 37584749
[TBL] [Abstract] [Full Text] [Related]
[Next]
